BOULDER, Colo. --(BUSINESS WIRE)--May 31, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton , Chief Executive Officer of Biodesix , will present and host in-person 1x1 investor meetings at William

BOULDER, Colo. --(BUSINESS WIRE)--May 25, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, presented original data in four separate poster presentations at the ISPOR ( International Society for Pharmaceutical and Outcomes

BOULDER, Colo. --(BUSINESS WIRE)--May 24, 2023-- Biodesix, Inc. a leading diagnostics company, is proud to announce that its Chief Financial Officer, Robin Harper Cowie , has been appointed to the Colorado BioScience Association (CBSA) board of directors.

BOULDER, Colo. --(BUSINESS WIRE)--May 18, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in

   First quarter 2023 Core Lung Diagnostic revenue of $8.6 million increased 86% over the comparable period in 2022; Record number of Core Lung Diagnostic tests delivered in Company history; Conference Call and Webcast Today at 4:30 p.m. ET   BOULDER, Colo.

BOULDER, Colo. --(BUSINESS WIRE)--Apr. 27, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for first quarter ended March 31, 2023 after the close of trading on Thursday, May

Fourth Quarter and Fiscal Year 2022 Core Lung Diagnostic Revenue of $8.2 Million and $29.3 Million Increased 51% and 57% over the comparable 2021 periods, respectively 2023 Total Revenue Guidance Expected to be Between $52 Million and $55 Million - Mid-point of the range represents growth in excess

BOULDER, Colo. --(BUSINESS WIRE)--Feb. 28, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton , Chief Executive Officer of Biodesix , will participate in a fireside chat and host in-person 1x1

BOULDER, Colo. --(BUSINESS WIRE)--Feb. 21, 2023-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2022 before the open of trading